Literature DB >> 18712668

Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma.

G H Piao1, W H Piao, Y He, H H Zhang, G Q Wang, Z Piao.   

Abstract

The retinoblastoma protein-interacting zinc finger gene RIZ1 is a putative tumor suppressor gene, and the inactivation of the RIZ1 is frequently found in tumors through a loss of mRNA expression. In order to understand the role of RIZ1 inactivation in the tumorigenesis of hepatocellular carcinoma (HCC), we detected the RIZ1 promoter methylation status in 39 HCCs using a methylation specific PCR (MSP) method, and carried out LOH study with marker P704. We also assessed the associations between the methylation status and clinicopathological parameters, tumor size, tumor differentiation, and fractional allelic loss (FAL). The results showed that the RIZ1 promoter methylated both in advanced tumors (>3 cm), (18/31, 58.0%) and in early tumors (<3 cm), (4/8, 50.0%). There were 54.6% (12/22) tumors with hyper-methylation in the low FAL group and 45.5% (10/22) in the high FAL group. Moreover, the DNA methylation of the RIZ1 promoter was found not only in the poorly differentiated tumors (12/22, 54.6%), but also in the well differentiated tumors (10/22, 45.5%). Among the 22 HCCs (22/39, 56.4%) that showed hyper-methylation at the RIZ1 promoter region, 3 cases showed biallelic methylation. Interestingly, one case showed hyper-methylation on one allele and a loss of heterozygosity (LOH) on the other allele. In other words, 4 HCCs showed the biallelic inactivation of the RIZ1. These results suggest that the inactivation of the RIZ1 by DNA methylation at its promoter region is involved in the tumorigenesis of HCC, particularly in the early stage of disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18712668     DOI: 10.14670/HH-23.1171

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  12 in total

Review 1.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 2.  Histone demethylases and cancer.

Authors:  Sotirios C Kampranis; Philip N Tsichlis
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

3.  Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells.

Authors:  Fei Zhao; Yan Chen; Ling-lan Zeng; Rui Li; Rong Zeng; Lu Wen; Yuan Liu; Chun Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

4.  Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.

Authors:  H Y Cheng; T Zhang; Y Qu; W J Shi; G Lou; Y X Liu; Y Y Zhang; L Cheng
Journal:  Cancer Gene Ther       Date:  2016-10-07       Impact factor: 5.987

5.  Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma.

Authors:  Eric J Formeister; Masato Tsuchiya; Hideki Fujii; Svitlana Shpyleva; Igor P Pogribny; Ivan Rusyn
Journal:  Mutat Res       Date:  2010-08-22       Impact factor: 2.433

Review 6.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

Review 7.  DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma.

Authors:  Sumadi Lukman Anwar; Ulrich Lehmann
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

8.  Genetic and epigenetic changes in fibrosis-associated hepatocarcinogenesis in mice.

Authors:  Grace Chappell; Kristy Kutanzi; Takeki Uehara; Volodymyr Tryndyak; Hue-Hua Hong; Mark Hoenerhoff; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  Int J Cancer       Date:  2013-12-14       Impact factor: 7.396

9.  Anticancer activity of the PR domain of tumor suppressor RIZ1.

Authors:  Wanpeng Sun; Ling Qiao; Qiang Liu; Lifeng Chen; Binbing Ling; Ramaswami Sammynaiken; Jian Yang
Journal:  Int J Med Sci       Date:  2011-02-21       Impact factor: 3.738

10.  Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review).

Authors:  Youhong Dong; Anping Wang
Journal:  Oncol Lett       Date:  2014-07-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.